CICC: Upgrade the target price of Kangbo Biotech (09926) to HK$225 and maintain "outperform" rating.

Zh tng cijng APP hu x, zhng jn fb ynbo chng, kng fng shngw (09926) shng bnnin shur tng b zngzhng 37.75%, yj fh goxng yq. Goxng wich jtun jn mng ling nin de yng c, x y "po yng hngy" pngj, shngdio AK112 lnghun chnggng l, bng jing Summit AK112 zi shuqun de ycng nr gzh. Ync, goxng df tioshng jtun mbioji 87.5% zh 225 gngyun. According to the Wisdom Financial APP, Zhongjin released a research report stating that Kangfang Biotech (09926) had a year-on-year revenue growth of 37.75% in the first half of the year, and its performance met the bank's expectations. The bank maintained its earnings forecast for the group for the next two years, reiterated the "outperform industry" rating, raised the clinical success rate of AK112, and included the forecast of Summit AK112's re-licensing in the valuation. Therefore, the bank significantly raised the group's target price by 87.5% to 225 Hong Kong dollars.